EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High diagnostic performance of plasma and cerebrospinal fluid beta‐synuclein for sporadic Creutzfeldt–Jakob disease

Samir Abu-Rumeileh iD, Steffen Halbgebauer, Giuseppe Mario Bentivenga, Lorenzo Barba iD, Simone Baiardi, Andrea Mastrangelo, Patrick Oeckl, Petra Steinacker, Angela Mammana, Sabina Capellari, Markus Otto, Piero Parchi iD

Annals of Clinical and Translational Neurology · 2023

DOI: 10.1002/acn3.51873 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2023. Verfasst von Samir Abu-Rumeileh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany. Hauptthemen laut MEDLINE: Creutzfeldt-Jakob Syndrome. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Fondation Thierry Latran.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Beta‐synuclein is a promising cerebrospinal fluid and blood biomarker of synaptic damage. Here we analysed its accuracy in the discrimination between sporadic Creutzfeldt–Jakob disease ( n = 150) and non‐prion rapidly progressive dementias ( n = 106). In cerebrospinal fluid, beta‐synuclein performed better than protein 14‐3‐3 (AUC 0.95 vs. 0.89) and, to a lesser extent, than total tau (AUC 0.92). Further, the diagnostic value of plasma beta‐synuclein (AUC 0.91) outperformed that of plasma tau (AUC 0.79) and neurofilament light chain protein (AUC 0.65) and was comparable to that of cerebrospinal fluid biomarkers. Beta‐synuclein might represent the first highly accurate blood biomarker for the diagnosis of sporadic Creutzfeldt–Jakob disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Creutzfeldt-Jakob SyndromeHumansbeta-Synuclein14-3-3 ProteinsBiomarkers

Substanzen

beta-Synuclein14-3-3 ProteinsBiomarkers

Autor:innen und Institutionen

  • Department of Neurology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
  • Department of Neurology, Ulm University Hospital, Ulm, Germany.
  • German Center for Neurodegenerative Diseases (DZNE e.V.), Ulm, Germany.
  • Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.
  • IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.

ORCID-Profile: Samir Abu-Rumeileh, Lorenzo Barba, Piero Parchi

Förderung

  • Ministero della Salute
  • Fondation Thierry Latran

Zitieren

APA

Abu-Rumeileh, S., Halbgebauer, S., Bentivenga, G. M., Barba, L., Baiardi, S., Mastrangelo, A., Oeckl, P., Steinacker, P., Mammana, A., Capellari, S., Otto, M., & Parchi, P. (2023). High diagnostic performance of plasma and cerebrospinal fluid beta‐synuclein for sporadic Creutzfeldt–Jakob disease. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.51873

Vancouver

Abu-Rumeileh S, Halbgebauer S, Bentivenga GM, Barba L, Baiardi S, Mastrangelo A, et al. High diagnostic performance of plasma and cerebrospinal fluid beta‐synuclein for sporadic Creutzfeldt–Jakob disease. Annals of Clinical and Translational Neurology. 2023. doi:10.1002/acn3.51873

BibTeX
@article{AbuRumeileh2023,
  author = {Abu-Rumeileh, Samir and Halbgebauer, Steffen and Bentivenga, Giuseppe Mario and Barba, Lorenzo and Baiardi, Simone and Mastrangelo, Andrea and Oeckl, Patrick and Steinacker, Petra and Mammana, Angela and Capellari, Sabina and Otto, Markus and Parchi, Piero},
  title = {High diagnostic performance of plasma and cerebrospinal fluid beta‐synuclein for sporadic Creutzfeldt–Jakob disease},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2023},
  doi = {10.1002/acn3.51873}
}
Kostenlos starten →